Stock Events

Stock Events

Avadel Pharmaceuticals 

$21.51
0
+$0.51+2.43% Thursday 08:54

Statistics

Day High
21.51
Day Low
21.51
52W High
-
52W Low
-
Volume
4
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

9MarExpected
Q3 2025
Q4 2025
0
0.02
0.04
0.06
Expected EPS
0.048
Actual EPS
N/A

Financials

-28.87%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
338.23MRevenue
-97.66MNet Income

Analyst Ratings

$20.20Average Price Target
The highest estimate is 22.50.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AVDL.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Jazz Pharmaceuticals
JAZZ
Mkt Cap8.35B
Jazz Pharmaceuticals focuses on developing and commercializing products for sleep disorders, directly competing with Avadel's narcolepsy treatments.
Axsome Therapeutics
AXSM
Mkt Cap6.74B
Axsome Therapeutics is involved in developing therapies for central nervous system disorders including narcolepsy, making it a direct competitor.
Heron Therapeutics
HRTX
Mkt Cap212.64M
Heron Therapeutics develops treatments for postoperative pain and other conditions, competing in the broader pharmaceutical market against Avadel's offerings.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap23.49B
Teva Pharmaceutical Industries has a broad portfolio that includes treatments for sleep disorders, directly competing with Avadel's narcolepsy drug.
Biogen
BIIB
Mkt Cap22.63B
Biogen focuses on neurological diseases including sleep disorders, positioning it as a competitor in the same therapeutic area as Avadel.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical division Janssen, competes across a wide range of therapeutic areas, including sleep disorders.
Novartis
NVS
Mkt Cap237.61B
Novartis offers a broad range of healthcare products that compete in various therapeutic areas, including those targeted by Avadel.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a diverse portfolio of drugs, including those for neurological conditions, competing with Avadel's focus areas.
Merck
MRK
Mkt Cap214.76B
Merck & Co. competes in the pharmaceutical market with a broad product line, including treatments for conditions that overlap with Avadel's target markets.

About

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Show more...
CEO
ISIN
IE00BDGMC594

Listings

BOATS
BOATS
AVDL.BOATS

0 Comments

Share your thoughts

FAQ

What is Avadel Pharmaceuticals stock price today?▼
The current price of AVDL.BOATS is $21.51 USD — it has increased by +2.43% in the past 24 hours. Watch Avadel Pharmaceuticals stock price performance more closely on the chart.
What is Avadel Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Avadel Pharmaceuticals stocks are traded under the ticker AVDL.BOATS.
What is Avadel Pharmaceuticals revenue for the last year?▼
Avadel Pharmaceuticals revenue for the last year amounts to 338.23M USD.
What is Avadel Pharmaceuticals net income for the last year?▼
AVDL.BOATS net income for the last year is -97.66M USD.
When did Avadel Pharmaceuticals complete a stock split?▼
Avadel Pharmaceuticals has not had any recent stock splits.